Stocklytics Platform
Asset logo for symbol REGN
Regeneron Pharmaceuticals
REGN72
$701.85arrow_drop_down0.84%-$6.01
S&P500
Asset logo for symbol REGN
REGN72

$701.85

arrow_drop_down0.84%

Performance History

Chart placeholder
Key Stats
Open$710.20
Prev. Close$708.25
EPS40.08
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
LOWHIGH
Day Range701.12
717.98
52 Week Range693.09
1,211.20
Ratios
EPS40.08

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals Inc (REGN) is a leading biotechnology company that specializes in the discovery, development, and commercialization of innovative medicines. With a focus on science-driven research, Regeneron has established itself as a trusted provider of therapies for a range of serious medical conditions. The company's dedication to scientific excellence has been recognized through numerous achievements and collaborations with renowned institutions.
The stock price history of Regeneron Pharmaceuticals Inc (REGN) reflects the company's consistent growth and success. Over the years, REGN stock has demonstrated a positive trend, providing investors with significant returns. This consistent performance is a testament to the company's strong leadership and commitment to advancing healthcare through groundbreaking therapies.
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Leonard S. Schleifer M.D., Ph.D.
Headquarters
Tarrytown
Employees
12099
Exchange
NASDAQ
add Regeneron Pharmaceuticals  to watchlist

Keep an eye on Regeneron Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Regeneron Pharmaceuticals 's (REGN) price per share?

The current price per share for Regeneron Pharmaceuticals (REGN) is $701.85. The stock has seen a price change of -$6.02 recently, indicating a -0.85% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Regeneron Pharmaceuticals (REGN)?

For Regeneron Pharmaceuticals (REGN), the 52-week high is $1.21K, which is 72.57% from the current price. The 52-week low is $693.1, the current price is 1.26% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Regeneron Pharmaceuticals (REGN) a growth stock?

Regeneron Pharmaceuticals (REGN) has shown an average price growth of -4.38% over the past three years. It has received a score of 58 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Regeneron Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Regeneron Pharmaceuticals (REGN) stock price performance year to date (YTD)?

As of the latest data, Regeneron Pharmaceuticals (REGN) has a year-to-date price change of -22.45%. Over the past month, the stock has experienced a price change of -5.73%. Over the last three months, the change has been -35.73%. Over the past six months, the figure is -33.36%. Looking at a longer horizon, the five-year price change stands at 87.56%.
help

Is Regeneron Pharmaceuticals (REGN) a profitable company?

Regeneron Pharmaceuticals (REGN) has a net income of $3.95B, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 93.26% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 33.43% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $13.12B, with a revenue growth rate of 7.76%, providing insight into the company's sales performance and growth. The gross profit is $12.23B. Operating income is noted at $4.05B. Furthermore, the EBITDA is $5.24B.
help

What is the market capitalization of Regeneron Pharmaceuticals (REGN)?

Regeneron Pharmaceuticals (REGN) has a market capitalization of $77.13B. The average daily trading volume is 705.49, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level